Science

Candida auris copies its entire genome to survive antifungal treatment, research reveals

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 15/10/2026, 09:10:23 UTC.

Briefings

Research from the University of Exeter and City St George's, University of London, published October 15, 2026, reveals Candida auris survives antifungal treatment by creating multiple genome versions. The study identified a mutated CRZ1 gene affecting cell wall integrity, though the specific survival mechanism remains partially understood. This finding highlights a novel adaptive strategy in a pathogen that has caused significant global health challenges.

Key points

• Candida auris creates multiple versions of its entire genome to survive antifungal treatment, specifically mutating the CRZ1 gene involved in cell wall integrity.
• The research team led by the University of Exeter and City St George's, University of London, identified CRZ1 as a key gene mutated during this adaptive process.

Context and limitations

The study provides initial evidence of genome duplication and CRZ1 mutation but does not confirm the exact survival mechanism. Further research is required to fully understand how this genomic variation confers resistance to antifungal drugs.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 15/10/2026, 09:11:40 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeicrn45zif6hhc6isv4vmcwcbfq4mmfyjqiq7sarbjmupibzpjy23q